Growth patterns of patients with Noonan syndrome: correlation with age and genotype

SHP2 sails from physiology to pathology

(2015) Mylène Tajan et al.   European Journal of Medical Genetics

Survival and Morbidity of Preterm Children Born at 22 Through 34 Weeks’ Gestation in France in 2011

(2015) Pierre-Yves Ancel et al.   JAMA Pediatrics

Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations

(2014) Zhi-Hong Yu et al.   BIOCHEMISTRY

LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity

(2014) Mylène Tajan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Ras-GTPase activity of neurofibromin restrains ERK-dependent FGFR signaling during endochondral bone formation

(2013) Koichiro Ono et al.   HUMAN MOLECULAR GENETICS

Noonan syndrome

(2013) Amy E Roberts et al.   LANCET

Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS/MAPK pathway

(2012) Alexsandra C. Malaquias et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Health and Quality of Life in Adults with Noonan Syndrome

(2012) Gerhard Binder et al.   JOURNAL OF PEDIATRICS

Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature

(2012) A. D. R. Serra-Nedelec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Noonan syndrome and clinically related disorders

(2011) Marco Tartaglia et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation

(2011) Xue Wu et al.   JOURNAL OF CLINICAL INVESTIGATION

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation

(2011) Talita M. Marin et al.   JOURNAL OF CLINICAL INVESTIGATION

A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome

(2011) Marjorie J. Lindhurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Growth curves for height in Noonan syndrome

(2010) David R. Witt et al.   CLINICAL GENETICS

Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation

(2010) Peng-Chieh Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3  Signaling

(2010) T. Edouard et al.   MOLECULAR AND CELLULAR BIOLOGY

Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines

(2010) A. A. Romano et al.   PEDIATRICS

Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation

(2009) T. Araki et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome

(2008) M. Krenz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway

(2007) Marie Dance et al.   CELLULAR SIGNALLING